IQVIA, London, United Kingdom.
IRCCS Istituto Nazionale Tumori Regina Elena, Rome, Italy.
Appl Clin Inform. 2024 Aug;15(4):743-750. doi: 10.1055/s-0044-1788331. Epub 2024 Sep 11.
Multicenter precision oncology real-world evidence requires a substantial long-term investment by hospitals to prepare their data and align on common Clinical Research processes and medical definitions. Our team has developed a self-assessment framework to support hospitals and hospital networks to measure their digital maturity and better plan and coordinate those investments. From that framework, we developed PRISM for Cancer Outcomes: PR: agmatic I: nstitutional S: urvey and benchM: arking.
The primary objective was to develop PRISM as a tool for self-assessment of digital maturity in oncology hospitals and research networks; a secondary objective was to create an initial benchmarking cohort of >25 hospitals using the tool as input for future development.
PRISM is a 25-question semiquantitative self-assessment survey developed iteratively from expert knowledge in oncology real-world study delivery. It covers four digital maturity dimensions: (1) Precision oncology, (2) Clinical digital data, (3) Routine outcomes, and (4) Information governance and delivery. These reflect the four main data types and critical enablers for precision oncology research from routine electronic health records.
During piloting with 26 hospitals from 19 European countries, PRISM was found to be easy to use and its semiquantitative questions to be understood in a wide diversity of hospitals. Results within the initial benchmarking cohort aligned well with internal perspectives. We found statistically significant differences in digital maturity, with Precision oncology being the most mature dimension, and Information governance and delivery the least mature.
PRISM is a light footprint benchmarking tool to support the planning of large-scale real-world research networks. It can be used to (i) help an individual hospital identify areas most in need of investment and improvement, (ii) help a network of hospitals identify sources of best practice and expertise, and (iii) help research networks plan research. With further testing, policymakers could use PRISM to better plan digital investments around the Cancer Mission and European Digital Health Space.
多中心精准肿瘤学真实世界证据需要医院进行大量的长期投资，以准备其数据并就共同的临床研究流程和医学定义达成一致。我们的团队开发了一个自我评估框架，以支持医院和医院网络衡量其数字成熟度，并更好地规划和协调这些投资。基于该框架，我们开发了用于癌症结果的 PRISM：PR：agmatic I：nstitutional S：urvey 和 benchM：arking。
主要目标是开发 PRISM 作为评估肿瘤医院和研究网络数字成熟度的工具；次要目标是使用该工具创建一个超过 25 家医院的初始基准测试队列，作为未来发展的输入。
PRISM 是一个 25 个问题的半定量自我评估调查，从肿瘤真实世界研究交付方面的专家知识中迭代开发而来。它涵盖了四个数字成熟度维度：（1）精准肿瘤学，（2）临床数字数据，（3）常规结果，和（4）信息治理和交付。这些反映了从常规电子健康记录中进行精准肿瘤学研究的四个主要数据类型和关键推动因素。
在对来自 19 个欧洲国家的 26 家医院进行试点时，发现 PRISM 使用方便，其半定量问题在广泛的医院中都易于理解。初始基准测试队列中的结果与内部观点吻合良好。我们发现数字成熟度存在统计学上的显著差异，其中精准肿瘤学是最成熟的维度，而信息治理和交付则是最不成熟的维度。
PRISM 是一种轻量级的基准测试工具，可支持大规模真实世界研究网络的规划。它可以用于：（i）帮助单个医院确定最需要投资和改进的领域，（ii）帮助医院网络确定最佳实践和专业知识的来源，以及（iii）帮助研究网络规划研究。通过进一步的测试，政策制定者可以使用 PRISM 更好地规划围绕癌症任务和欧洲数字健康空间的数字投资。
